KTRA vs. ADMP, PRFX, HOTH, ALLR, BPTS, ONCR, ARTL, CALC, GRAY, and CLVSQ
Should you be buying Kintara Therapeutics stock or one of its competitors? The main competitors of Kintara Therapeutics include Adamis Pharmaceuticals (ADMP), PainReform (PRFX), Hoth Therapeutics (HOTH), Allarity Therapeutics (ALLR), Biophytis (BPTS), Oncorus (ONCR), Artelo Biosciences (ARTL), CalciMedica (CALC), Graybug Vision (GRAY), and Clovis Oncology (CLVSQ). These companies are all part of the "pharmaceutical preparations" industry.
Kintara Therapeutics vs.
Adamis Pharmaceuticals (NASDAQ:ADMP) and Kintara Therapeutics (NASDAQ:KTRA) are both small-cap medical companies, but which is the superior business? We will contrast the two companies based on the strength of their analyst recommendations, risk, profitability, earnings, community ranking, institutional ownership, valuation, media sentiment and dividends.
Adamis Pharmaceuticals received 319 more outperform votes than Kintara Therapeutics when rated by MarketBeat users. However, 88.24% of users gave Kintara Therapeutics an outperform vote while only 66.27% of users gave Adamis Pharmaceuticals an outperform vote.
Adamis Pharmaceuticals has a beta of 1.22, indicating that its stock price is 22% more volatile than the S&P 500. Comparatively, Kintara Therapeutics has a beta of 0.92, indicating that its stock price is 8% less volatile than the S&P 500.
Kintara Therapeutics has a net margin of 0.00% compared to Adamis Pharmaceuticals' net margin of -495.95%. Kintara Therapeutics' return on equity of 0.00% beat Adamis Pharmaceuticals' return on equity.
8.6% of Adamis Pharmaceuticals shares are owned by institutional investors. 1.3% of Adamis Pharmaceuticals shares are owned by insiders. Comparatively, 4.3% of Kintara Therapeutics shares are owned by insiders. Strong institutional ownership is an indication that endowments, hedge funds and large money managers believe a stock will outperform the market over the long term.
In the previous week, Adamis Pharmaceuticals had 4 more articles in the media than Kintara Therapeutics. MarketBeat recorded 4 mentions for Adamis Pharmaceuticals and 0 mentions for Kintara Therapeutics. Adamis Pharmaceuticals' average media sentiment score of 0.39 beat Kintara Therapeutics' score of 0.00 indicating that Adamis Pharmaceuticals is being referred to more favorably in the media.
Kintara Therapeutics has lower revenue, but higher earnings than Adamis Pharmaceuticals.
Summary
Adamis Pharmaceuticals and Kintara Therapeutics tied by winning 6 of the 12 factors compared between the two stocks.
New MarketBeat Followers Over Time
This chart shows the number of new MarketBeat users adding KTRA and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.
Media Sentiment Over Time
This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.
Kintara Therapeutics Competitors List
Related Companies and Tools
